Jazz Pharmaceuticals Plc, a Dublin-based, Nasdaq-listed company that has built a diversified pharmaceutical business through acquisitions, has made an offer to acquire Celator Pharmaceuticals Inc and its late-stage product for treating acute myeloid leukaemia (AML) for about $1.5 billion.
